Navigation Links
CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS

ear with a four-fold arimoclomol dose increase, subject to FDA clearance.

"We are encouraged by the favorable results of this open-label trial, which make us even more eager to proceed at an even higher dose level in further clinical testing," stated CytRx's President and CEO Steven A. Kriegsman. "The comparison of these clinical results with historical data suggests a trend toward clinical improvement. Our Phase IIb efficacy study will be placebo-controlled and is planned to include a larger number of volunteers, treated for a longer period of time with a four-fold higher dose than that used in the open-label clinical trial."

The open-label extension clinical trial was initiated in February 2006 as ALS volunteers completing CytRx's placebo-controlled, double-blind, dose-ranging Phase IIa clinical trial were provided the opportunity to receive arimoclomol treatment for up to an additional six months. A total of 69 patients were treated in the open-label arimoclomol trial for six months, while the historical control followed 99 subjects for 12 months.

In the open-label trial, arimoclomol treatment was demonstrated to be safe as indicated by the lack of clinically-significant changes in vital signs and laboratory values, compared to baseline values. Arimoclomol was also well-tolerated with a total drop-out rate of 11.6%, or an average of 1.3% per month, during the six-month trial. This compares favorably with the historical control drop-out rate of 33.3%, or an average of 2.75% per month, for the 12-month trial.

CytRx's planned Phase IIb clinical trial is currently expected to include approximately 390 ALS patients enrolled at 30 to 35 U.S. and Canadian clinical sites treated for nine months. The trial is expected to be completed approximately 18 months after enrollment begins.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therap
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
2. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
3. CytRx Announces Positive Results of Arimoclomol in Preclinical Stroke Recovery Studies
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
Post Your Comments:
(Date:1/14/2014)... North America,s leading business partnering event ... 30 th edition of its annual conference at the ... 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... specialty chemical companies will take part in the conference, which ...
(Date:1/14/2014)... Animal Emergency Critical Care, a LifeCentre partner practice, located at ... is the first in Loudoun County to ... Susan M. Barnes , Medical Director, is a well-seasoned veterinarian ... Cole Taylor , are avid scuba divers. "As altitude skiers and ...
(Date:1/14/2014)... 14, 2014 Equashield ( http://www.equashield.com ... drugs, today announced that it has achieved 60% ...   Equashield,s closed systems reduce the ... and other medical professionals who prepare and administer ...
Breaking Medicine Technology:Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Equashield's Sales Grow by 60% in 2013 2
... 6 The FDA has approved new technology that ... faster. The SonoCine Automated Whole-breast Ultrasound Method and is ... Arizona Breastnet, in Scottsdale. This unique technology is designed ... yearly mammography screening. Until now, ultrasound has only been ...
... , MARLTON, N.J., Dec. 4 Thermographic ... Center in Marlton, New Jersey continues to provide superior ... dental, TMJ and sinus regions to assist in the ... , Thermography utilizes infrared imaging cameras that "read" the ...
Cached Medicine Technology:New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3Discover Health Through Awareness 2Discover Health Through Awareness 3
(Date:4/17/2014)... Arias, M.D., Ph.D., at The University of Texas Health ... superbug that caused a bloodstream infection in a Brazilian ... of The New England Journal of Medicine . ... of highly-resistant bacteria known as methicillin-resistant Staphylococcus aureus ... hospital and community-associated infections. The superbug has also acquired ...
(Date:4/17/2014)... The world is less than 40 years away from ... people and governments, according to a top scientist at ... time in human history, food production will be limited ... water and energy," said Dr. Fred Davies, senior science ... issues could become as politically destabilizing by 2050 as ...
(Date:4/17/2014)... its status as the leading weapon against the deadly ... with new research indicating it simply needs to be ... of the cheap anti-malarial drug chloroquine in treating and ... more than half a million people each year around ... developed resistance to chloroquine, but research carried out at ...
(Date:4/16/2014)... A team that includes scientists from the School of ... San Antonio, Johns Hopkins University and St. Mary,s University reported ... to infect the body. , The fungal pathogen Candida ... and is the most common fungal pathogen to infect humans. ...
(Date:4/15/2014)... , , CHAMPAIGN, Ill. Scientists have solved a decades-old medical mystery ... way to fight invasive fungal infections, which kill about 1.5 million ... of action of amphotericin, an antifungal drug that has been in ... nearly as toxic to human cells as it is to the ...
Breaking Medicine News(10 mins):Health News:New MRSA superbug emerges in Brazil 2Health News:Food shortages could be most critical world issue by mid-century 2Health News:Scientists find new way to fight malaria drug resistance 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3
... physician and hospital is decreasing, study finds, , , TUESDAY, April ... physician would be the one who directed your health care ... comfort level. , But, in reality, that type of seamless ... Americans. , A new study found that among Medicare patients, ...
... pillow giveaway and Danny Seo appearance on HSN. , ... ... Earth Day, Simmons Bedding Company is encouraging consumers to ... the company,s Natural Care® mattress and pillow collection, which is endorsed ...
... RONKONKOMA, N.Y., April 21 NBTY, Inc. (NYSE: NTY ... marketer of nutritional supplements, today announced it will web cast a ... Web site, ( www.NBTY.com ), on Friday, April 24, ... for the fiscal second quarter will be issued at 4:30 PM ...
... CHAPEL HILL, N.C., April 21 New research with ... and managed markets is now available in the Best ... and consulting firm Best Practices, LLC.To review key topics ... links to each of the two new studies at ...
... WASHINGTON, April 21 FRC Action ... the Senate Finance Committee approved Gov. Kathleen Sebelius,s nomination ... vote on Gov. Sebelius,s nomination reflects growing grassroots opposition ... her failure to disclose deep financial ties to late-term ...
... Nursing baby brings cardiovascular benefits decades later, study suggests, ... just good for baby, it may also boost mom,s ... , Women in their 60s who had breast-fed for ... 10 percent less likely to develop cardiovascular disease, and ...
Cached Medicine News:Health News:Transition From Home to Hospital Rarely Seamless 2Health News:Transition From Home to Hospital Rarely Seamless 3Health News:Simmons Celebrates Earth Day by Encouraging Consumers To "Sleep Green" 2Health News:Simmons Celebrates Earth Day by Encouraging Consumers To "Sleep Green" 3Health News:Simmons Celebrates Earth Day by Encouraging Consumers To "Sleep Green" 4Health News:Simmons Celebrates Earth Day by Encouraging Consumers To "Sleep Green" 5Health News:NBTY to Web Cast Fiscal Second Quarter Conference Call 2Health News:NBTY to Web Cast Fiscal Second Quarter Conference Call 3Health News:Best Practice Database Adds Research Highlighting Effective Data Gathering Approaches for Competitive Intelligence and Successful Activities for Gaining Maximum Payer Access and Insights 2Health News:Breast-feeding a Boon to Mom's Heart 2Health News:Breast-feeding a Boon to Mom's Heart 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: